Author

Thuyen N. Nguyen

Stanford MedicineORCID 0000-0002-4513-9335Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Assay:metabolomics· 1

Frequent Co-Authors

Julien SageiD· 3 shared Griffin G. HartmanniD· 2 shared Albert Mao LiiD· 1 shared Alexandros P. DrainasiD· 1 shared Ali Taleb AbdallahiD· 1 shared Àlvaro Quintanal-VillalongaiD· 1 shared Anca M. PașcaiD· 1 shared Andrea C. ChaikovskyiD· 1 shared

Activity by Year

2023-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 26 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Julien SageORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cell BiologyeLifePeer-reviewedApr 30, 2026

THE FAM53C/DYRK1A axis regulates the G1/S transition of the cell cycle

Taylar Hammond, Jong Bin Choi, Miles W. Membreño…·Julien Sage

This study identifies FAM53C as a regulator of the G1/S cell cycle transition, showing it interacts with DYRK1A and affects cell cycle progression in cultured cells and organoids.

1 citation

humanexperimental assay

𝕏 PostBluesky

Cancer BiologybioRxivPreprintMar 31, 2026

Cell state-specific metabolic networks govern ferroptosis versus apoptosis in small cell lung cancer

Jun W. Kim, Christina M. Bebber, Yuqin Dai…·Julien Sage

The paper identifies metabolic differences between ASCL1-high and low SCLC cells, showing that ASCL1-high cells resist ferroptosis via BH4/BH2 antioxidants and are vulnerable to combined cysteine depletion and BH4/BH2 inhibition.

DOI 10.64898/2026.03.27.714827

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintDec 6, 2023

Development of pre-clinical murine models for fibrolamellar hepatocellular carcinoma

Andy He, Garry L. Coles, Griffin G. Hartmann…·Julien Sage

This study develops a novel transgenic mouse model of fibrolamellar hepatocellular carcinoma (FLC) and highlights challenges in establishing ex vivo cell models from FLC tumors.

2 citations

mouseexperimental assay

𝕏 PostBluesky